The FDA’s Oncologic Drugs Advisory Committee narrowly voted against the approval of Zusduri, citing the lack of a completely ...

Martin Kulldorff and Robert Malone, both outspoken vaccine skeptics, have received compensation for their expert ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Scientists and analysts express concern that the newly appointed members—which include known anti-vaxxers—could relitigate ...

The rehired staff, who number around 460, work with the CDC’s viral disease prevention efforts and sexual health testing labs ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, ...

The loss of special government employee status for four members of the CDC’s Advisory Committee on Immunization Practices ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead ...